Somewhat Positive Media Coverage Somewhat Unlikely to Affect American Renal Associates (ARA) Stock Price

Press coverage about American Renal Associates (NYSE:ARA) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. American Renal Associates earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.9114321120751 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several equities research analysts recently weighed in on the company. Zacks Investment Research raised American Renal Associates from a “sell” rating to a “hold” rating in a report on Tuesday, February 20th. SunTrust Banks set a $20.00 target price on American Renal Associates and gave the stock a “buy” rating in a research report on Thursday, December 21st. Finally, Leerink Swann lowered American Renal Associates from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $17.00 to $27.00 in a research report on Thursday, March 8th.

How to Become a New Pot Stock Millionaire

NYSE:ARA traded down $0.47 during trading hours on Tuesday, hitting $16.64. 63,173 shares of the company were exchanged, compared to its average volume of 169,778. The firm has a market cap of $532.63, a P/E ratio of 27.30, a P/E/G ratio of 0.80 and a beta of 1.92. The company has a quick ratio of 1.17, a current ratio of 1.20 and a debt-to-equity ratio of 4.28. American Renal Associates has a one year low of $9.91 and a one year high of $24.07.

American Renal Associates (NYSE:ARA) last announced its earnings results on Tuesday, March 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.03. The business had revenue of $194.40 million during the quarter, compared to analyst estimates of $195.15 million. American Renal Associates had a positive return on equity of 14.51% and a negative net margin of 1.00%. American Renal Associates’s revenue for the quarter was down 2.5% compared to the same quarter last year. During the same period last year, the company earned $0.26 EPS. equities research analysts expect that American Renal Associates will post 0.73 EPS for the current year.

WARNING: This report was originally reported by registrarjournal.com and is the property of of registrarjournal.com. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://registrarjournal.com/2018/04/17/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-american-renal-associates-ara-stock-price.html.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Insider Buying and Selling by Quarter for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply